Ukko
Ukko utilizes a computational protein design and AI platform to develop immuno-therapeutics for individuals with life-threatening food allergies. The company engineers new versions of allergens that avoid triggering allergic responses while re-educating the immune system to build tolerance. Their primary focus is on reducing the health and economic impact of food sensitivities through protein micro-engineering.
Healthtech
Biotechnology
Artificial Intelligence
Therapeutics
Funding summary
- Total raised
- €33.0M
- Funding rounds
- 1
Investors in Ukko
Investors on record for Ukko. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Ukko?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors